Physicians' Academy for Cardiovascular Education

Familial Hypercholesterolemia

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD

Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

A novel small binding protein that targets PCSK9

3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD

Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype

3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD

Familial Hypercholesterolemia and Lp(a)

10' education - July 14, 2020 - Nick Nurmohamed, MD

Familial Hypercholesterolemia: Why and how to screen?

10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD

Tools to detect FH

10' education - June 23, 2020 - Rens Reeskamp, MD

Familial hypercholesterolemia in children and adolescents

10' education - June 2, 2020 - Bert Wiegman, MD, PhD

One step closer to controlling LDL-c levels in HoFH with PCSK9i

3' education - Apr. 9, 2020 - Dirk Blom, PhD

Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH

3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020

The mechanism of action of bempedoic acid

Feb. 2, 2020

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?

5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD

Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia

5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD

Efforts to move universal cholesterol screening before the age of 20 forward

3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD

Challenges for screening and treatment of FH patients in clinical cardiology

5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME

Identifying patients for PCSK9 therapy

10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME

Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

PCSK9 inhibition across a wide spectrum of patients: One size fits all?

10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME

Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality

10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME

CV outcomes with a PCSK9 inhibitor: FOURIER study

3' education - Mar. 16, 2017

A minority of FH patients is identified and labeled as such, which impacts treatment

10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)

Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment

3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)

Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?

10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands

Impacting lipid disorders through personalised healthcare

3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.

Accumulating clinical data on PCSK9 inhibition: What are the key lessons?

10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA

Lipid Management 2020: A glance at the future

10' education - Sep. 24, 2015

A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia

3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling

FH: Call for investigators to get involved

3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein

Monogenic FH and clinically defined FH remain largely undertreated

Literature - Oct. 25, 2021 - Björnsson E et al. - Arterioscler Thromb Vasc Biol. 2021

This study investigated the prevalence and impact of monogenic FH and clinically defined FH in a large proportion of the Icelandic population.

Women with FH want more information on pregnancy in relation to their condition

Literature - Oct. 20, 2021 - Klevmoen M et al. - Atherosclerosis. 2021

This study investigated the duration of pregnancy-related off-statin periods in Norwegian and Dutch women with FH. Among these women, 86% wanted to receive more information on pregnancy and breastfeeding in relation to FH.

FDA approval for PCSK9i in children with heterozygous FH of 10 years and older

News - Sep. 27, 2021

The US Food and Drug Administration (FDA) approved evolocumab as treatment for pediatric patients with heterozygous FH of 10 years and older to reduce LDL-c levels.

Global registry study shows that FH is diagnosed late and poorly managed

Literature - Sep. 13, 2021 - EAS Familial Hypercholesterolaemia Studies Collaboration (FHCS) - The Lancet 2021

The EAS FHSC have created a global registry of FH patients for the surveillance of FH worldwide. Findings of the present study on the adult population show that FH is diagnosed late and LDL-c targets are often not achieved.

PCSK9 siRNA reduces LDL-c in patients with and without polyvascular disease

News - Sep. 6, 2021

ESC 2021 This pooled, post-hoc analysis of ORION-9, -10, and -11 showed that inclisiran significantly reduced LDL-c compared placebo in patients with and without polyvascular disease.

Treament intertia for lipid-lowering therapy in patients with FH and CVD

Literature - Aug. 9, 2021 - Langer A et al. - J Am Heart Assoc. 2021

Physician reminders for recommended LLT led to an increase in the proportion of patients with FH and/or CVD achieving LDL-c treatment goals. However, treatment inertia exists in patients with FH, including those with established CVD.

Statin therapy during pregnancy?

5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD
Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Is it time to reconsider the recommendations on lipid-lowering therapy in pregnant women? In order to answer this question, prof. Banach provides an overview of studies on this topic.

Increased atherogenicity of LDL and impaired HDL function in children with FH

News - June 7, 2021

EAS 2021 This study showed that children with familiar hypercholesterolemia had an increased susceptibility of LDL particles to form aggregates and a reduced cholesterol efflux capacity of HDL compared to healthy children.

Real-world data of PCSK9i use in FH patients

News - June 2, 2021

EAS 2021 An interim-analysis of the HEYMANS study showed that the majority of FH (both HeFH and HoFH) patients have a history of CV events and comorbidities. Initiation of evolocumab in these patients resulted in reduced LDL-c levels, maintained throughout the study.

Genetic testing for autosomal dominant hypercholesterolemia in Norwegian patients and relatives

Literature - Apr. 20, 2021 - Leren TP and Bogsrud MP. - Atherosclerosis. 2021

Heterozygous LDLR gene mutations were most prevalent when screening for autosomal dominant hypercholesterolemia in hypercholesterolemia patients and relatives from Norway.

Pooled analysis of three trials with PCSK9 siRNA in patients with HeFH or ASCVD

Literature - Apr. 20, 2021 - Wright RS et al. - J Am Coll Cardiol. 2021

This pooled patient-level analysis of three phase 3 trials (ORION-9, -10 and -11) shows that inclisiran reduces LDL-c on average by 50.7% compared to placebo in patients on maximally tolerated statin-therapy.

Registry data of PCSK9i in patients with high CV risk and hypercholesterolemia

Literature - Apr. 13, 2021 - Gaudet D, et al. - Eur J Prev Cardiol 2021

The ODYSSEY APPRISE study showed in general good tolerability for alirocumab in high CV risk patients and ~50% reduction in LDL-c after 12 weeks of alirocumab treatment.